Lilly Acquires AtaiBeckley to Advance Depression Therapies
INDIANAPOLIS and NEW YORK, July 16, 2026 Eli Lilly and Company has announced a definitive agreement to acquire AtaiBeckley...
Psychiatry
Advertisement
TG Therapeutics Launches Phase 2 BRIUMVI Trial
NEW YORK, July 6, 2026 TG Therapeutics, Inc. announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI®...
AtaiBeckley Completes Patient Dosing in Phase 2b VLS-01 TRD Trial
NEW YORK, July 6, 2026 AtaiBeckley Inc. announced that the final patient has been dosed in Elumina, its international...
Oryzon Raises €12M to Accelerate Clinical Development
MADRID, Spain & CAMBRIDGE, Mass., July 1, 2026 Oryzon Genomics S.A. announced the successful completion of a €12 million...
Otsuka Reports Positive Phase 3b Results for Centanafadine
TOKYO, Japan & PRINCETON, N.J., June 26, 2026 Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc....
Advertisements
NRx Pharmaceuticals Highlights Real-World Ketamine Depression Data
MIAMI, June 5, 2026 NRx Pharmaceuticals, Inc. announced that new real-world evidence presented at the 2026 American Society of...
Definium Therapeutics Begins Phase 3 DT120-ODT Study
WALTHAM, Mass., May 12, 2026 Definium Therapeutics announced that the first patient has been dosed in the pivotal ASCEND...
Johnson & Johnson Highlights CAPLYTA Superiority in MDD Study
TITUSVILLE, NEW JERSEY, May 04, 2026 Johnson & Johnson has announced new findings demonstrating that CAPLYTA® (lumateperone) achieved the...
FDA Clears CAPLYTA® as New Adjunctive Therapy for Depression
Titusville, New Jersey – November 6, 2025 – Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and...
Advertisement
